Introduction to the Offering
The medical technology sector in India is experiencing exponential growth, driven by advanced healthcare infrastructure and increasing demand for specialized cardiac solutions. Stepping into this dynamic market space, Sahajanand Medical Technologies has announced its main-board public offering. Aiming to raise capital through a complete offer for sale framework, this offering opens doors for institutional and retail market participants to stake a claim in a globally recognized medical device manufacturing enterprise.
Core Business Operations
Founded in October 2001, Sahajanand Medical Technologies Limited stands as a prominent medical technology enterprise. The organization specializes in designing, developing, manufacturing, and marketing technologically advanced clinical devices, focusing heavily on structural heart solutions and vascular interventions.
- Diverse Product Catalog: Manufactures coronary stents, balloons, transcatheter aortic valve implantation (TAVI) modules, peripheral drug-coated options, and specialized occluders.
- Global Footprint: Products reach patients across 77 countries, backed by advanced manufacturing plants located in India and Thailand.
- Innovation Driven: Holds over 100 granted patents worldwide with numerous applications actively in pipeline stages, operating specialized research and development hubs.
Offering Timeline and Schedule
Tracking the lifecycle milestones of the public issue from commencement to final market debut is critical for strategic allocation. Below is the detailed progression schedule represented cleanly for clarity.
| Milestone Event | Tentative Date |
|---|---|
| Offering Opening Date | October 15, 2026 |
| Offering Closing Date | October 19, 2026 |
| Basis of Allotment Finalization | October 21, 2026 |
| Initiation of Refunds | October 22, 2026 |
| Credit of Securities to Demat | October 22, 2026 |
| Market Listing Date | October 23, 2026 |
Timeline Progress Tracker:
Issue Details and Lot Size Structure
The public offering size totals ₹475.48 crores, executed entirely via an offer for sale format. The pricing band is set between ₹327 and ₹344 per equity share with a face value of ₹1.
| Application Category | Lots Required | Shares Allocated | Capital Requirement (Upper Price) |
|---|---|---|---|
| Retail Individual (Minimum) | 1 | 43 | ₹14,792 |
| Retail Individual (Maximum) | 13 | 559 | ₹1,92,296 |
| Small High Net Worth (Min) | 14 | 602 | ₹2,07,088 |
| Big High Net Worth (Min) | 68 | 2924 | ₹10,05,856 |
Financial Performance Overview
An evaluation of the restated consolidated financial data demonstrates steady operational expansion and scaling profitability profiles over recent fiscal periods.
| Financial Metric (₹ Crore) | Period Ended Jun 2026 | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|---|
| Total Assets | 1,309.00 | 1,276.43 | 1,094.90 | 970.58 |
| Total Income | 354.33 | 1,218.73 | 1,035.96 | 908.59 |
| Profit After Tax (PAT) | 15.09 | 69.08 | 25.15 | -7.35 |
| EBITDA | 48.58 | 170.66 | 128.02 | 110.05 |
| Net Worth | 631.72 | 616.05 | 545.23 | 526.30 |
Key Performance Indicators & Valuation Metrics
Understanding operational efficiency and valuation multipliers helps determine whether the enterprise is reasonably priced compared to industry benchmarks.
- Return on Equity (ROE): 10.35% ( FY 2026 )
- Return on Capital Employed (ROCE): 11.57% ( FY 2026 )
- Debt to Equity Ratio: 0.27 ( FY 2026 )
- Price to Earnings (P/E Multiplier): ~57.91x based on post-issue metrics.
- Market Capitalization: Approximately ₹3,496.65 Crores at the upper price ceiling.
Strategic SWOT Analysis
Strengths
- Extensive international distribution channels across 77 countries.
- Robust R&D framework holding numerous global patents.
- High-barrier entry sector expertise in specialized healthcare devices.
Weaknesses
- 100% Offer for Sale implies zero capital infusion directly into company growth from this event.
- Exposure to foreign exchange fluctuations given international trade revenue.
Opportunities
- Expanding medical tourism and domestic healthcare access across emerging economies.
- Continuous product pipeline commercialization.
Threats
- Stringent global regulatory approval processes and compliance updates.
- Intense competition from multinational medical tech giants.
Corporate Promoters & Shareholding Structure
The enterprise is guided by experienced leadership and promoters including Bhargav Dhirajlal Kotadia, Dhirajlal Vallabhbhai Kotadia, Priyanka Dhirajlal Cohen, and the Shree Hari Trust. Pre-issue promoter holding stands at 40.82%, which adjusts to 36.2% following the conclusion of the public offering.
Registrar and Lead Management Details
Registrar to the Issue: MUFG Intime India Private Limited serves as the official registrar, handling registry queries, processing application forms, and managing security allotment procedures.
Book Running Lead Managers: Managed by prominent financial advisors including Motilal Oswal Investment Advisors, Avendus Capital, HSBC Securities, and Nuvama Wealth Management.
Conclusion
Sahajanand Medical Technologies presents an intriguing opportunity for participants interested in specialized healthcare sectors. Backed by solid technological innovation, multi-country distribution networks, and improved profitability metrics, the enterprise commands a strong position in interventional cardiology. However, participants should thoroughly assess their risk tolerance, review the Red Herring Prospectus (RHP), and align choices with their broader asset allocation strategies before applying.